Table 5.
Utilization of genomic testing (any type) on estrogen-positive breast cancer patients in the COVID-19 Registry
| Core (COVID-19) | Core (usual) | Surgical specimen (COVID-19) | Surgical specimen (usual) | Not performed | |
|---|---|---|---|---|---|
| No. of patients | 162 | 170 | 12 | 437 | 734 |
| Tumor size, cm | 1.6 | 1.5 | 1.7 | 1.3 | 1.6 |
| Patient age, years |
60 OR of 5-year age increase 0.89 (p = 0.0001) |
59 OR of 5-year age increase 0.86 (p = 0.008) |
63 | 63 | 68 |
| Node-positive |
25 (15.4%) OR of genomic testing on core (COVID) with node-positive = 4.0 (p = 0.001) |
49 (28.8%) OR of genomic testing on core (usual) with node-positive = 8.9 (p = 0.001) |
0 | 19 (4.3) | 121 (16.5) |
| NET (COVID) | 125 (77.2) | 32 (18.8) | 5 (41.7) | 58 (13.3) | 264 (36) |
| NET (usual) | 2 (1.2) | 34 (20) | 0 | 6 (1.4) | 64 (8.7) |
| NCT (COVID) | 17 (10.5) | 3 (1.8) | 0 | 1 (0.2) | 15 (2.0) |
| NCT (usual) | 5 (3.1) | 39 (22.9) | 0 | 1 (0.2) | 92 (12.5) |
| Primary surgery (COVID) | 2 (1.2) | 2 (1.2) | 0 | 6 (1.4) | 19 (2.6) |
| Primary surgery (usual) | 11 (6.8) | 60 (35.3) | 7 (58.3) | 365 (83.5) | 280 (38.1) |
Data are expressed as n (%) unless otherwise specified
COVID-19 coronavirus disease 2019, OR odds ratio